Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06408649 · ClinicalTrials.gov registry record
Post-market Clinical Follow-up Study of Alcon TOTAL30® Contact Lenses (Lehfilcon A)
A clinical trial, sponsored by Alcon Research.
- Terminated
- Registry status
- 129
- Enrollment target
NCT06408649: Clinical Trial study, sponsored by Alcon Research.
NCT06408649 is a clinical trial that was terminated before completion, run by Alcon Research. The registered enrollment target is 129 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06408649 was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- 129 participants
- Enrollment target
Study Summary
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to continuously assess the visual performance and safety of TOTAL30 Sphere and TOTAL30 for Astigmatism contact lenses in a real-world setting across a broad variety of patients through routine clinical practices.
Primary Outcome
Visual acuity (VA) assessed per the investigator's standard of care with study lenses in place.
Interventions
- DEVICE Lehfilcon A toric contact lenses
- DEVICE Lehfilcon A spherical contact lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2025-04-22 |
Why NCT06408649 stopped before completion
NCT06408649 is an observational study that tracks outcomes without assigning an intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Lehfilcon A toric contact lenses is the first listed.
NCT06408649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06408649 about?
NCT06408649 is a clinical study titled "Post-market Clinical Follow-up Study of Alcon TOTAL30® Contact Lenses (Lehfilcon A)". The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to continuously assess the visual performance and safety of TOTAL30 Sphere and TOTAL30 for Astigmatism contact lenses in a real-world setting across a broad variety of patients through routine clinical practices.
What is the current status of trial NCT06408649?
This trial is currently terminated. The enrollment target is 129 participants. The study started on 2024-11-15. Estimated completion is 2025-04-22.
What interventions are being tested in trial NCT06408649?
The interventions under investigation include: Lehfilcon A toric contact lenses (DEVICE), Lehfilcon A spherical contact lenses (DEVICE).
Who is sponsoring clinical trial NCT06408649?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI